Korro Bio’s Promising KRRO-110 Developments and Strong Financial Position Justify Buy Rating
Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Buy rating on Korro Bio (KRRO – Research Report). The associated price ...
manilatimes1d
Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates
Research and Development (R&D) Expenses: R&D expenses were $16.0 million for the three months ended September 30, 2024, as compared to $14.0 million for the same period in 2023. The increase was ...
Buy Rating for Legend Biotech’s CARVYKTI: Strong Market Performance and Future Potential
Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Legend Biotech (LEGN – Research Report) and keeping the price ...
Investing6d
4 Biotech Stocks With AI, Machine Learning Prowess
Korro Bio (NASDAQ:KRRO) aims to "discover, develop and commercialize a new class of RNA therapies informed by human genetics ...
Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments
Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...
RNA editing promises to go where DNA editing can’t
The first two and some forms of obesity are associated with single-point mutations. Some other companies using ADAR enzymes ...
Investing1d
Korro Bio Inc (KRRO)
Featured here, the Balance Sheet for Korro Bio Inc, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 10 period ending ...
Yahoo Finance2d
Korro Bio, Inc. (KRRO)
After hours: 12 November at 5:17 pm GMT-5 ...
American Association of Individual Investors3d
Which Is a Better Investment, AbbVie Inc or Novo Nordisk A/S (ADR) Stock?
The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat ...